Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing antibody-based therapeutics. Following the 2024 separation from its former parent, the company now centers on ozekibart (INBRX-109) and INBRX-106, with additional discovery-stage programs and no approved commercial products yet.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueIncludes ozekibart (INBRX-109) and INBRX-106, which are being advanced through clinical trials.
Early-stage biologic programs and research assets not yet in clinical development.
Non-product revenue recognized from licensing and assignment agreements with partners.
Clinical, manufacturing, and research activities managed through third-party CROs and CDMOs.
Customers
The company does not sell approved products commercially, so its current counterparties are primarily licensing partners, research collaborators, and service providers rather than end-market patients or hospitals. Its future customers would likely be healthcare providers and patients if any therapeutic candidate is approved and commercialized. Today, the business model depends on partner-funded or partner-enabled value creation rather than product sales.
Buy rights to programs or provide upfront/option payments tied to asset access and development milestones.
Support preclinical studies, clinical trials, and manufacturing scale-up for the company's pipeline.
Would use the company's therapies if any candidate reaches approval and commercialization.
Potential buyers of ozekibart or other assets in transactions intended to unlock value.
Strategy
Management is focused on advancing INBRX-106 through clinical development while evaluating alternatives to monetize ozekibart (INBRX-109) in a way that preserves tax efficiency and stockholder value. The company is also preparing for possible commercialization of approved assets, but near-term execution remains centered on clinical data generation, capital preservation, and external partnerships.
Clinical data is the main value driver for a pre-commercial biotech and determines future partnering or approval prospects.
A transaction could unlock value and reduce dependence on internal funding while minimizing dilution.
The company has no product revenue and relies on external financing to fund R&D and corporate overhead.
Geography
The company is headquartered in the United States and its operations are primarily U.S.-based, including clinical development, management, and laboratory/office functions. The reports provided do not disclose meaningful country-level revenue concentration, and current revenue is limited to license fee income rather than product sales. Geography matters mainly through U.S. regulatory oversight, domestic financing conditions, and exposure to global supply-chain and tariff risks affecting outsourced manufacturing inputs.
Risks
The company faces the typical risks of a clinical-stage biotech: trial failure, regulatory setbacks, and the need for additional capital before any product revenue exists. Its specific risks also include dependence on third-party manufacturers and service providers, as well as uncertainty around any transaction to monetize ozekibart. Global trade policy, tariffs, and macro volatility can further raise development costs and disrupt supply chains.
- Clinical development and regulatory failureImpact: HighLikelihood: High
INBRX-106 and ozekibart are still clinical-stage, so negative data or regulatory setbacks could materially reduce value.
Exposure: Phase 2/3 oncology and biologics development
- Financing and dilution riskImpact: HighLikelihood: High
With no commercial product revenue, the company may need additional capital to fund ongoing R&D and operations.
Exposure - Dependence on third-party manufacturers and CROs/CDMOsImpact: HighLikelihood: Medium
The company does not own manufacturing facilities and relies on a limited number of external providers for raw materials and clinical supply.
Exposure - Ozekibart monetization uncertaintyImpact: MediumLikelihood: Medium
A transaction may not occur, may take longer than expected, or may not deliver the intended tax or value benefits.
Exposure: Strategic transaction execution
- Tariffs and geopolitical supply-chain disruptionImpact: MediumLikelihood: Medium
Higher import costs or supply interruptions could affect biologic raw materials and clinical trial continuity.
Exposure: Global sourcing and manufacturing inputs
Accounting
Judgemental itemsRevenue is recognized when contractual obligations such as transfer of licenses, materials, and know-how are satisfied.
Impact: Can create lumpy quarterly revenue from collaboration agreements
Clinical trial, contract manufacturing, and personnel costs are expensed as incurred, making results sensitive to trial cadence.
Impact: Quarterly operating loss can swing with study activity and vendor timing
Laboratory and office leases create fixed obligations through 2028 with extension options.
Impact: Affects right-of-use assets, lease liabilities, and cash commitments
The 2025 Loan Agreement introduced financing costs and interest burden.
Impact: Impacts liquidity, leverage, and net loss
Similar listed companies
Publicly listed companies with a comparable business focus.
Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances)
IN8bio, Inc
INAB · Biological Products, (No Diagnostic Substances)
Instil Bio, Inc.
TIL · Biological Products, (No Diagnostic Substances)
Indaptus Therapeutics, Inc.
INDP · Pharmaceutical Preparations
Enveric Biosciences, Inc.
ENVB · Pharmaceutical Preparations
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Last updated: 24/09/2026